Evaluation Form

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice

DATE	date	LOCATION	location

Demographics

Physician: ❏ Yes ❏ No ❏ Other Please specify_____

Type of Practice: ❏ Full-time ❏ Part-time ❏ Solo ❏ Group ❏ Office ❏ Hospital ❏ Other

LEARNING OBJECTIVES: New Horizons in Dyslipidemia Management in Primary Care

After participating in this activity, I am now better able to:

1. Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently completed clinical trials

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardio vascular disease

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

4. Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

LEARNING OBJECTIVES: Case 2 - LDL-C: How Low Do You Go?

Upon completion of this case based session, participants will be able to:

1. Apply the recent CCS Dyslipidemia guidelines to clinical practice

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Discuss the importance of lowering LDL-C to target and select the appropriate therapeutic options to achieve guideline recommended targets

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Explain the evidence and safety data for achieving very low LDL-C levels

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

abetes & Cardiovascular Disease

d session, participants will be able to:

es for risk of macro and microvascular disease

sagree	Neutral	Agree
2	3	4

ection for your patients with diabetes

sagree	Neutral	Agree
2	3	4

pies to help reach the LDL-C target

sagree	Neutral	Agree
2	3	4

LEARNING OBJECTIVES: Case 3 - ASCVD with Multiple CV Risk Factors

Upon completion of this case based session, participants will be able to:

1. Identify patients with ASCVD and with multiple CV risk factors and those who have especially high risk features (eg: PAD)

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Prioritize treatment options in alignment with patient priorities

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Identify circumstances requiring use of statin-add-on therapies to achieve goal

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

4. Review safety and efficacy of PCSK9 inhibitors in specific high risk populations

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

5. Discuss safety and CV risk reduction benefits of very low LDL-C goals

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

Speaker   speaker1

Was effective in Presenting Material:

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

1. Review the diagnostic criteria for Familial Hypercholesterolemia

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

2. Apply the newly proposed Canadian definition of Familial Hypercholesterolemia

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

3. Employ evidence-based recommendations to LDL-C targets in this population

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

ias in any part of the program? ❑ Yes ❑ No

Speaker speaker2

Was effective in Presenting Material:

Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

ias in any part of the program? ❑ Yes ❑ No

This Program

Content enhanced my knowledge

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Addressed my most pressing questions

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Promoted improvements or quality in health care

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Was scientifically rigorous and evidence-based

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Provided appropriate and effective opportunities for active learning
(ie., case studies, discussion, Q &A, etc)

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Provided an opportunity for interaction with my peers

Strongly disagree		Neutral		Strongly agree
1	2	3	4	5

Please indicate with CAnMEDS roles you felt were addressed during this educational activity.

- ❑ Family Medicine Expert
- ❑ Collaborator
- ❑ Communicator
- ❑ Manager
- ❑ Health Advocate
- ❑ Professional
- ❑ Scholar

Based on your participation in this program, please select all applicable statement(s):

- ❑ I gained new strategies/skills/information that I can apply to my area of practice.
- ❑ I plan to implement new strategies/skills/information into my practice.
- ❑ I need more information before I can implement new strategies/skills/information into my practice behavior
- ❑ This program will not change my practice, as my current practice is consistent with the information presented.
- ❑ This program will not change my practice, as I do not agree with the information presented.

What strategies/changes do you plan to implement into your practice?

What barriers do you see to making a change in your practice?

Future Topics of Interest / Additional Comment & Suggestions

Thank you for your feedback!